BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qiang G, Huang W, Liang C, Xu R, Yan J, Xu Y, Wang YE, DA J, Shi B, Guo Y, Liu D. Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma. Oncol Lett 2016;11:1769-77. [PMID: 26998075 DOI: 10.3892/ol.2016.4154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yao G, Zhou Y, Gu Y, Wang Z, Yang M, Sun J, Luo Q, Zhao H. Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis. J Cancer 2020;11:5511-7. [PMID: 32742498 DOI: 10.7150/jca.46414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gerbaudo VH, Kim CK. PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet? Nucl Med Mol Imaging 2017;51:3-10. [PMID: 28250852 DOI: 10.1007/s13139-016-0453-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Sun XY, Chen TX, Chang C, Teng HH, Xie C, Ruan MM, Lei B, Liu L, Wang LH, Yang YH, Xie WH. SUVmax of 18FDG PET/CT Predicts Histological Grade of Lung Adenocarcinoma. Acad Radiol 2021;28:49-57. [PMID: 32113879 DOI: 10.1016/j.acra.2020.01.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wang C, Dong X, Sun X, Zhang R, Xing L. Association of radiomic features with epidermal growth factor receptor mutation status in non-small cell lung cancer and survival treated with tyrosine kinase inhibitors. Nucl Med Commun 2019;40:1091-8. [PMID: 31469811 DOI: 10.1097/MNM.0000000000001076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Jansen RW, van Amstel P, Martens RM, Kooi IE, Wesseling P, de Langen AJ, Menke-Van der Houven van Oordt CW, Jansen BHE, Moll AC, Dorsman JC, Castelijns JA, de Graaf P, de Jong MC. Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget 2018;9:20134-55. [PMID: 29732009 DOI: 10.18632/oncotarget.24893] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
6 Guo Y, Zhu H, Yao Z, Liu F, Yang D. The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis. Eur J Radiol 2021;141:109792. [PMID: 34062472 DOI: 10.1016/j.ejrad.2021.109792] [Reference Citation Analysis]
7 Du B, Wang S, Cui Y, Liu G, Li X, Li Y. Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis. BMJ Open 2021;11:e044313. [PMID: 34103313 DOI: 10.1136/bmjopen-2020-044313] [Reference Citation Analysis]